Two investigational medicines for hepatocellular carcinoma and dementia with Lewy bodies have been granted Innovation Passports through the UK’s Innovative Licensing and Access Pathway (ILAP). The designation recognizes their potential to address unmet clinical needs and accelerate development. The ILAP, a UK-wide initiative led by the Medicines and Healthcare products Regulatory Agency (MHRA), NHS England, NICE, and other partners, enables early regulatory and market access guidance for innovative therapies. The awarded products are still in development, with future availability dependent on safety, effectiveness, and value evidence. Applications for the next ILAP round, open until 4 November 2026, are now accepted. The program aims to streamline collaboration between developers, regulators, and healthcare providers to improve patient access to transformative treatments.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.